Navigation Links
Pharmac to Phase Out Aropax, Well-known Antidepressant

Government Drug Agency, Pharmac, is in the process of doing away with a commonly used antidepressant, Aropax. //

Pharmac intends to phase out the ‘Aropax’ brand of paroxetine and bring in the generic alternative ‘Loxamine’. It is estimated that Aropax is used by about 49,000 New Zealanders.

This move has drawn flak from psychiatrists in Australasia. Yet, the agency maintains that both drugs are the same, except for the appearance and the packaging. Further, this move is expected to result in a saving of $45 million over a three year period.

Dr Allen Fraser, chairman of the New Zealand national committee of the Royal Australian and New Zealand College of Psychiatrists, said, "What concerns the college is the insistence in this process that patients currently on paroxetine, the Aropax form, must either pay for it, or be changed to the new form. We had advocated that where the clinician prescribing the medication believed it was in the patient's interest to remain on their current medication, it should remain fully subsidized for those persons. They clearly have not accepted that as a standard. We will still be pursuing that because that's the major issue for us. If patients have been doing well on their current medication, they deserve to still have access to it.”

Pharmac deputy medical director Dr Dilky Rasiah said, "At present, people prescribed paroxetine for the first time need to have previously had a trial of fluoxetine, another antidepressant. Once Loxamine is funded, it will not be subject to this requirement, which will give people easier access to it."

Dr Rasiah said that tests have confirmed the effectiveness of Loxamine brand, at par with Aropax , so patients will not experience any difficulties with change in drug.



'"/>




Page: 1

Related medicine news :

1. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
2. Pharmaceutical giant offers AIDS related antifungal drug free to 50 countries
3. Medicis Pharmaceutical company enters pediatric market
4. Pharmacies in for a dose of bitter medicine
5. Pharmacia may take 51.5 percent Abbott stake
6. Pharmaceutical companies are targeting patients
7. FDA approves Watson Pharmaceuticals Oxytrol patch
8. Pharmacist’s Role in Medication Error
9. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
10. Indian Pharmaceutical Industries Stops Manufacturing And Sale Of Valdecoxib
11. Pharmaceutical industries grant for R&D to be monitored
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... ... ... Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health and Mental ... exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards took place ... BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to receive an ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: